Biogen Inc. Announces First Trimester Fiscal 2025 Results

Biogen Inc. disclosed its financial outcomes for the first trimester of fiscal 2025, showcasing a notable 6% increase in revenue, totaling $2.4 billion, compared to the same period in 2024.

Financial Performance Highlights

Despite the revenue growth, the company experienced a decline in GAAP diluted earnings per share, which fell to $1.64. Additionally, the net income attributable to Biogen Inc. for the quarter ending March 31 was reported at $240.5 million.

CEO's Perspective on Growth Strategy

"Biogen delivered strong first-quarter results, supporting our strategy for long-term growth. We are encouraged by the transformation in our commercial product portfolio, with approximately 45% of total product revenue in the first quarter derived from important medicines outside of our MS business," stated CEO Christopher Viehbacher.